Basiliximab

Efficacy and safety evaluation in kidney transplantation

Claudio Ponticelli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 receptor (IL-2R). When administered intravenously at a dosage of 20 mg at the time of transplantation and 4 days later, basiliximab saturates the alpha chain of IL-2R for 4 weeks. Areas covered: This review evaluates the efficacy and safety of basiliximab in kidney transplantation. Randomized controlled trials showed that basiliximab can significantly reduce the incidence of acute rejection without increasing the risk of adverse events. When compared with other antibodies used for induction, basiliximab showed efficacy and safety profiles similar to daclizumab, another monoclonal antibody directed against the alpha chain of IL-2R. In comparison with rabbit anti-thymocyte globulins (rATG), basiliximab showed a similar efficacy. However, in patients at higher risk of rejection, rATG proved to be more effective. No serious safety problems related to basiliximab have been reported. Expert opinion: There is a solid evidence that basiliximab can significantly decrease the risk of acute rejection in kidney transplant recipients without increasing adverse events. This can allow decreased dosage or avoidance of glucocorticoids and reduced dosage of calcineurin inhibitors. On the basis of efficacy, tolerability, ease of administration, and cost effectiveness, basiliximab may be considered the drug of choice for the prophylaxis of acute rejection in standard renal transplant recipients.

Original languageEnglish
Pages (from-to)373-381
Number of pages9
JournalExpert Opinion on Drug Safety
Volume13
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Kidney Transplantation
Safety
Interleukin-2 Receptor alpha Subunit
Antilymphocyte Serum
Monoclonal Antibodies
Interleukin-4 Receptors
Rabbits
Kidney
basiliximab
Expert Testimony
Glucocorticoids
Cost-Benefit Analysis
Interleukin-2
Randomized Controlled Trials
Transplantation
Antibodies
Incidence
Pharmaceutical Preparations

Keywords

  • Basiliximab
  • Immunosuppression
  • Induction therapy
  • Interleukin-2
  • Monoclonal antibodies
  • Renal transplantation

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Basiliximab : Efficacy and safety evaluation in kidney transplantation. / Ponticelli, Claudio.

In: Expert Opinion on Drug Safety, Vol. 13, No. 3, 03.2014, p. 373-381.

Research output: Contribution to journalArticle

Ponticelli, Claudio. / Basiliximab : Efficacy and safety evaluation in kidney transplantation. In: Expert Opinion on Drug Safety. 2014 ; Vol. 13, No. 3. pp. 373-381.
@article{706476e4ca38405cb17c7b401db2e427,
title = "Basiliximab: Efficacy and safety evaluation in kidney transplantation",
abstract = "Introduction: Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 receptor (IL-2R). When administered intravenously at a dosage of 20 mg at the time of transplantation and 4 days later, basiliximab saturates the alpha chain of IL-2R for 4 weeks. Areas covered: This review evaluates the efficacy and safety of basiliximab in kidney transplantation. Randomized controlled trials showed that basiliximab can significantly reduce the incidence of acute rejection without increasing the risk of adverse events. When compared with other antibodies used for induction, basiliximab showed efficacy and safety profiles similar to daclizumab, another monoclonal antibody directed against the alpha chain of IL-2R. In comparison with rabbit anti-thymocyte globulins (rATG), basiliximab showed a similar efficacy. However, in patients at higher risk of rejection, rATG proved to be more effective. No serious safety problems related to basiliximab have been reported. Expert opinion: There is a solid evidence that basiliximab can significantly decrease the risk of acute rejection in kidney transplant recipients without increasing adverse events. This can allow decreased dosage or avoidance of glucocorticoids and reduced dosage of calcineurin inhibitors. On the basis of efficacy, tolerability, ease of administration, and cost effectiveness, basiliximab may be considered the drug of choice for the prophylaxis of acute rejection in standard renal transplant recipients.",
keywords = "Basiliximab, Immunosuppression, Induction therapy, Interleukin-2, Monoclonal antibodies, Renal transplantation",
author = "Claudio Ponticelli",
year = "2014",
month = "3",
doi = "10.1517/14740338.2014.861816",
language = "English",
volume = "13",
pages = "373--381",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Basiliximab

T2 - Efficacy and safety evaluation in kidney transplantation

AU - Ponticelli, Claudio

PY - 2014/3

Y1 - 2014/3

N2 - Introduction: Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 receptor (IL-2R). When administered intravenously at a dosage of 20 mg at the time of transplantation and 4 days later, basiliximab saturates the alpha chain of IL-2R for 4 weeks. Areas covered: This review evaluates the efficacy and safety of basiliximab in kidney transplantation. Randomized controlled trials showed that basiliximab can significantly reduce the incidence of acute rejection without increasing the risk of adverse events. When compared with other antibodies used for induction, basiliximab showed efficacy and safety profiles similar to daclizumab, another monoclonal antibody directed against the alpha chain of IL-2R. In comparison with rabbit anti-thymocyte globulins (rATG), basiliximab showed a similar efficacy. However, in patients at higher risk of rejection, rATG proved to be more effective. No serious safety problems related to basiliximab have been reported. Expert opinion: There is a solid evidence that basiliximab can significantly decrease the risk of acute rejection in kidney transplant recipients without increasing adverse events. This can allow decreased dosage or avoidance of glucocorticoids and reduced dosage of calcineurin inhibitors. On the basis of efficacy, tolerability, ease of administration, and cost effectiveness, basiliximab may be considered the drug of choice for the prophylaxis of acute rejection in standard renal transplant recipients.

AB - Introduction: Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 receptor (IL-2R). When administered intravenously at a dosage of 20 mg at the time of transplantation and 4 days later, basiliximab saturates the alpha chain of IL-2R for 4 weeks. Areas covered: This review evaluates the efficacy and safety of basiliximab in kidney transplantation. Randomized controlled trials showed that basiliximab can significantly reduce the incidence of acute rejection without increasing the risk of adverse events. When compared with other antibodies used for induction, basiliximab showed efficacy and safety profiles similar to daclizumab, another monoclonal antibody directed against the alpha chain of IL-2R. In comparison with rabbit anti-thymocyte globulins (rATG), basiliximab showed a similar efficacy. However, in patients at higher risk of rejection, rATG proved to be more effective. No serious safety problems related to basiliximab have been reported. Expert opinion: There is a solid evidence that basiliximab can significantly decrease the risk of acute rejection in kidney transplant recipients without increasing adverse events. This can allow decreased dosage or avoidance of glucocorticoids and reduced dosage of calcineurin inhibitors. On the basis of efficacy, tolerability, ease of administration, and cost effectiveness, basiliximab may be considered the drug of choice for the prophylaxis of acute rejection in standard renal transplant recipients.

KW - Basiliximab

KW - Immunosuppression

KW - Induction therapy

KW - Interleukin-2

KW - Monoclonal antibodies

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=84896722910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896722910&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.861816

DO - 10.1517/14740338.2014.861816

M3 - Article

VL - 13

SP - 373

EP - 381

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -